{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:47:37Z","timestamp":1761166057288,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaapos.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jaapos.2023.01.002","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T02:08:44Z","timestamp":1673057324000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bevacizumab for retinopathy of prematurity and neurodevelopment"],"prefix":"10.1016","volume":"27","author":[{"given":"Gil","family":"Binenbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaapos.2023.01.002_bib1","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/bjo.2008.156208","article-title":"Promise and potential pitfalls of anti-VEGF drugs in retinopathy of prematurity","volume":"93","author":"Darlow","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaapos.2023.01.002_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaapos.2023.01.002_bib3","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bjo.2008.141481","article-title":"Anti-vascular endothelial growth factor and retinopathy of prematurity","volume":"92","author":"Sears","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaapos.2023.01.002_bib4","first-page":"10.e1","article-title":"Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity","volume":"27","author":"Wallace","year":"2023","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2023.01.002_bib5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Pediatric Eye Disease Investigator Group (PEDIG). Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2023.01.002_bib6","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaapos.2023.01.002_bib7","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaapos.2023.01.002_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3928\/23258160-20190605-01","article-title":"Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP","volume":"50","author":"Hilkert Rodriguez","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jaapos.2023.01.002_bib9","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1055\/s-0040-1710556","article-title":"Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up","volume":"38","author":"Zayek","year":"2021","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.jaapos.2023.01.002_bib10","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"Pediatric Eye Disease Investigator Group. A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2023.01.002_bib11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ophtha.2020.12.028","article-title":"Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal anti-vascular endothelial growth factor","volume":"128","author":"Barry","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2023.01.002_bib12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3928\/23258160-20200228-07","article-title":"Functional and morphologic findings at four years after intravitreal bevacizumab or laser for type 1 ROP","volume":"51","author":"Lepore","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"}],"container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853123000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853123000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:25:39Z","timestamp":1761078339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091853123000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1091853123000046"],"URL":"https:\/\/doi.org\/10.1016\/j.jaapos.2023.01.002","relation":{},"ISSN":["1091-8531"],"issn-type":[{"type":"print","value":"1091-8531"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bevacizumab for retinopathy of prematurity and neurodevelopment","name":"articletitle","label":"Article Title"},{"value":"Journal of American Association for Pediatric Ophthalmology and Strabismus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaapos.2023.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}